Danaher Corporation
Upcoming event
Related Content
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Research & Development
Cytiva enters research partnership with SRTIGET for next-gen genomic medicine
The pair aim to expand the role of lipid nanoparticle technology into gene therapy delivery, including applications in cancer and inherited blood diseases, CNS delivery for neurological disorders where current methods fail and in vivo stem cell modification that could eliminate toxic conditioning regimens
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
Collaboration is key to advancing cell and gene therapy
The potential for cell and gene therapies to address a wide range of diseases is reflected in the sheer size of the pipeline. As of the start of this year, more than 2000 gene and modified cell therapies, such as chimeric antigen receptor T-cell (CAR-T) treatments, were under development, along with 800-plus non-genetically modified cell therapies(1)